Meridian Bioscience Stock News

Meridian Bioscience Inc. (VIVO) shares closed this week 24.4% higher than it did at the end of last week. The stock is currently up 30.4% year-to-date, down 3.1% over the past 12 months, and up 117.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $27.23 and as low as $21.50 this week.Trading volume this week was 14.8% lower than the 10-day average and 9.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -571.2% The company's stock price performance over the past 12 months beats the peer average by -52.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 31.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Meridian Bioscience <> rose following its Q1 results and a raised fiscal 2022 guidance.The company said net revenues in Q1 fiscal were $88.3M, only 5% below the record $92.9M in

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience, Inc.'s (VIVO) CEO Jack Kenny on Q1 2022 Results - Earnings Call Transcript

Meridian Bioscience Inc VIVO has posted Q1 FY22 sales of $88.2 million, down 4.9% Y/Y, sharply beating the consensus of $70.29 million. Get the Inside Access Traders Are Using to Profit More and Win

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open.The consensus EPS Estimate is $0.27 (-52.6% Y/Y) and the

Meridian Bioscience <> announced that the National Institute of Health ((NIH)) awarded an additional $2.5M worth of funding to accelerate the development of its Revogene

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. Johnson & Johnson (NYSE: JNJ) got the ball rolling on large-cap biopharma earnings, with

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.